MyMeds&Me announces exit to a private equity company
We are pleased to announce that MyMeds&Me, a digital pharma company, has been acquired by Drug Safety and Pharmacovigilance Services Solutions (DSS), a portfolio company of private equity firm Stanley Capital Partners.
UK-headquartered, MyMeds&Me captures safety data directly from patients, healthcare professionals and Pharma teams across multiple intake channels through its global SaaS platform, Reportum®. The company has a global client base which includes some of the world’s leading pharmaceutical companies.
As the sole institutional investor in MyMeds&Me having been invested for 9 years, this relationship typifies Albion's approach to investment where we take the long term view and provide patient capital to allow businesses time to flourish.
Dr Andrew Elder, Partner Albion said:
The acquisition of MyMeds&Me is a tribute to the category-leading software platform Andrew and his team have built for the life sciences industry. The team have been committed to building a product that streamlines the management and understanding of drug safety information. This acquisition is an important milestone in their journey to provide a best-in-class pharmacovigilance solution.
Dr Andrew Rut, CEO and founder of MyMeds&Me, commented:
MyMeds&Me is proud to be joining the DSS family, providing us with a framework to expand our high-quality technology offering. With the industry’s ever greater focus on patient engagement, the deployment of innovative technology combined with complementary services from DSS will enable our customers to revolutionise their pharmacovigilance strategy and optimise the safe use of their medicines.